-
[show abstract]
[hide abstract]
ABSTRACT: This study evaluated the effects of ZD1839, an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, on nasopharyngeal carcinoma (NPC) both in vitro and in vivo. Influence of ZD1839 alone or combined with cisplatin on the NPC cell line CNE2 was detected by MTT assay with flow cytometry assessment of cell cycle distribution and apoptosis rates. Nude mice NPC xenografts were also used to evaluate the effects of ZD1839 alone or combined with cisplatin. The Student's t test evaluated statistical significance. ZD1839 alone or combined with cisplatin inhibited CNE2 cell line proliferation. ZD1839 induced CNE2 cell cycle arrest in the G1 phase, and higher concentrations induced apoptosis. Xenograft tumors were significantly smaller when treated with 200 mg/kg ZD1839, cisplatin, or cisplatin combined with 100 mg/kg ZD1839 than untreated controls. ZD1839 (200 mg/kg) alone showed good tumor inhibition effects, reduction of tumor weights, and smaller tumor volume without loss of body weight. ZD1839 (200 mg/kg) might provide a good and effective therapeutic reagent for NPC.
Asian Pacific journal of cancer prevention: APJCP 01/2013; 14(3):1787-90. · 0.66 Impact Factor
-
Yan-Xia Shi,
Qing Xia,
Rou-Jun Peng, Zhong-Yu Yuan,
Shu-Sen Wang,
Xin An,
Ye Cao,
Yu-Ting Tan,
Ying Jin,
Xiu-Yu Cai,
Yue-Li Sun,
Xiao-Yu Teng,
Dong-Geng Liu,
Wen-Qi Jiang
[show abstract]
[hide abstract]
ABSTRACT: The clinical significance of bilateral breast cancer is unclear and its influence on prognosis is controversial. We compared the characteristics and prognosis of bilateral breast cancer and unilateral breast cancer.
Our study included 4,183 patients with breast cancer who were treated at Sun Yat-sen University Cancer Center between January 1, 2000, and December 31, 2007. Bilateral breast cancer was categorized as synchronous (within 3 months) or metachronous (diagnosed after 3 months of first cancer). SPSS was used for data analysis.
106 (2.5%) and 31 (0.7%) patients were diagnosed with metachronous and synchronous bilateral cancer. Women with bilateral cancer had more frequent postmenopause, HER-2 negativity, and advanced disease than in patients with unilateral cancer. Young age at diagnosis, invasive lobular carcinoma, ER/PR negativity, HER-2 positivity, radiation, large tumor size (T > 5 cm), and stage III disease of the first cancer were risk factors for contralateral cancer. The 5-year disease-free survival and overall survival rates were 76 and 83% for unilateral cancer, while 32 and 72% for bilateral cancer (P = 0.000 for both).
Bilateral cancer was associated with shorter disease-free survival and overall survival than unilateral cancer. The prognosis of metachronous bilateral cancer, especially those diagnosed within 2 years after the first cancer was significantly worse than synchronous bilateral cancer.
Journal of Cancer Research and Clinical Oncology 01/2012; 138(4):705-14. · 2.56 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: This study aimed to assess possible interactive effects of coping styles and psychological stress on depression and anxiety symptoms in Chinese women shortly after diagnosis of breast cancer.
Four hundred and one patients with breast cancer were face-to-face interviewed by trained research staff according to a standardized questionnaire including information on socio-demographic characteristics, psychological stress, coping styles, and anxiety and depressive symptoms. Interactive effects were assessed by hierarchical multiple regression analyses.
There were significant associations of the four domains of psychological stress with anxiety and depressive symptoms except for the relationship between "worrying about health being harmed" and depressive symptoms. "Abreaction coping behavior" and "escaping coping behavior" significantly increased the level of both anxiety and depressive symptoms; whereas an "active coping style" resulted in significant decrease. The interaction of "active coping behavior" with "worrying about health being harmed" significantly increased the risk of the anxiety symptoms, while adopting "self-relaxing coping behavior" was associated with significant decrease. The interaction of "worry about daily life and social relationship being restricted" with "escaping coping behavior" significantly increased the risk of the depressive symptoms.
The results of this study suggest that certain coping styles might moderate the association of psychological stress with anxiety and depressive symptoms in Chinese women with breast cancer.
Asian Pacific journal of cancer prevention: APJCP 01/2012; 13(4):1645-9. · 0.66 Impact Factor
-
Yan-Xia Shi,
Yu-Ting Tan, Zhong-Yu Yuan,
Shu-Sen Wang,
Rou-Jun Peng,
Xin An,
Ye Cao,
Ying Jin,
Xiu-Yu Cai,
Yue-Li Sun,
Xiao-Yu Teng,
Dong-Geng Liu
[show abstract]
[hide abstract]
ABSTRACT: Trastuzumab has been the standard treatment in first-line treatment of HER-2-positive advanced breast cancer (H2ABC). This study explored whether the delayed and repeated use of trastuzumab could influence overall survival (OS). A total of 128 patients with H2ABC who had received at least one line of trastuzumab-based regimens were included. The primary endpoint was OS defined as from the date of first diagnosis of H2ABC to death. The median OS of initiating trastuzumab in first-line group (n = 56), in the second-line group (n = 32), and the third- or more-line group (n = 40) was 40.6 m, 39.5 m, and 38 m, respectively (P = 0.867). For patients who had received over one line of trastuzumab (n = 46), the median OS was 44 m, and for those receiving only one line (n = 67), it was 27.6 m (P = 0.059). The delayed use of trastuzumab has no negative effect on the OS of patients with H2ABC. There is a trend of improved OS over the repeated use of trastuzumab.
Medical Oncology 02/2011; 29(1):39-47. · 2.14 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Foxp3⁺ regulatory T lymphocytes (Tregs) usually act as an immune suppressor and correlate with poorer survival in malignancies. This study aims to investigate the distribution and characterization of Foxp3(+) subset in peripheral blood mononuclear cells (PBMCs) and tumor tissues from extranodal NK/T cell lymphoma (ENKTL). Our study showed the percentage of Foxp3⁺ subset from PBMC was significantly higher than that of healthy individuals (P<0.001). The Foxp3⁺ subset from PBMCs expressed CD45RO, CTLA4, GITR, CCR7, and had an IL-10(high)IFNγ⁺TGFβ⁺IL-2(low)IL-17(low) cytokine secreting phenotype. Interestingly, the existence of EBV antigen-specific CD8⁺Foxp3⁺ Tregs was discovered in ENKTL. Furthermore, the high density of Foxp3⁺ TILs was associated with improved progression-free survival (PFS) in ENKTL patients (P<0.05). Collectively, our study implicates that EBV antigens could induce antigen-specific CD8⁺Foxp3⁺ Tregs in ENKTL, and Foxp3⁺ TILs is an independent factor for PFS in ENKTL.
International journal of biological sciences 01/2011; 7(7):1027-36. · 2.70 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of the present study was to assess the association of psychological stress and social support with anxiety and depressive symptoms in Chinese newly diagnosed breast cancer patients.
Four hundred and one patients with breast cancer were recruited. Their demographic characteristics, psychological stress and social support were determined with a structured questionnaire, and their anxiety and depressive symptoms were assessed with the Hospital Anxiety and Depression Scale.
Psychological stressors caused by breast cancer diagnosed originated from five major sources, as determined by factor analysis. These included "Worrying about health being harmed, " "Fear of decline of physical function, " "Fear of work being harmed, " "Worry about daily life and social relationship being restricted, " and "Fear of family being harmed. " Hierarchical linear regression analysis indicated that, after adjusting for gender, age, marital status, educational level, and duration of illness, solid social support can alleviate such symptoms.
The results of this study suggest that there are strong associations between patients' needs and psychological distress with newly diagnosed breast cancer. Social support might affect these associations in Chinese women with breast cancer.
Asian Pacific journal of cancer prevention: APJCP 01/2011; 12(10):2523-9. · 0.66 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The changes in therapeutic strategies were determined and the efficacy of radical mastectomy (RM) and modified radical mastectomy (MRM) on Chinese male breast cancer (MBC) patients was compared. Seventy MBC patients, with a median age of 61 years, were enrolled. The characteristics of MBC were compared in cohort A (1969-1997) and cohort B (1998-2009), and the prognosis was compared between the RM and MRM groups. Infiltrating ductal carcinoma accounted for 81.4% of all cases; 93.7% were estrogen receptor (ER)/progesterone receptor (PR)-positive. More patients in cohort B accepted multidisciplinary treatment, MRM, adjuvant chemotherapy, and endocrine therapy than those in cohort A; however, the 5-year overall survival rates were similar in the two cohorts. The overall survival curves, locoregional recurrence rates, and systematic metastatic rates were similar in the RM and MRM groups. Currently, more MBC patients receive conservative surgery; MRM may be equally effective as RM for MBC.
Breast (Edinburgh, Scotland) 12/2010; 19(6):450-5. · 2.09 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: It is not clear if there is a difference in prognosis between male breast cancer (MBC) and female breast cancer (FBC) patients. The aim of this study was to compare the prognosis of MBC and FBC patients in China and the prognosis of MBC and their corresponding postmenopausal FBC patients.
Thirty-five MBC patients who were treated at the Sun Yat-sen University Cancer Center between 1969 and 2004 were enrolled in the study. Seventy FBC patients who were matched with the MBC patients for TNM stage, year of diagnosis, and age at diagnosis were simultaneously enrolled in the study. A second group comprising 18 MBC patients and their corresponding 36 matched postmenopausal FBC patients were also enrolled. The whole group and the postmenopausal groups were compared for five- and ten-year survivals.
All the factors that could potentially affect prognosis were comparable among the groups except more FBC than MBC patients underwent endocrine therapy and a modified radical mastectomy. The 5- and 10-year survivals in the whole group were 81.6% and 60.3% for men and 90.7% and 73.5% for women (P = 0.02). The 5- and 10-year survival in the postmenopausal group was 82.5% and 100% for men and 66.0% and 85.9% for women (P = 0.159).
Chinese FBC patients had a better prognosis than Chinese MBC patients. However, MBC patients and their corresponding postmenopausal FBC patients had a similar prognosis.
Chinese medical journal 09/2010; 123(17):2347-52. · 0.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The brain is one of the most common metastatic sites of breast cancer. Brain metastases develop in 10%-15% of patients with breast cancer and are associated with poor prognosis. The purpose of this retrospective study was to analyze the clinical characteristics and survival of patients with brain metastases due to breast cancer of different subtypes and to identify the prognostic factors that affect clinical outcome.
A total of 89 patients with breast cancer brain metastases diagnosed between October 1997 and July 2008 at Sun Yat-sen University Cancer Center were included in this study. Among the 89 patients, the number of luminal A, luminal B, human epidermal growth factor receptor 2 (HER-2), and triple-negative (TN) subtypes were 30, 20, 16, and 14, respectively; 9 patients had an unknown subtype. The clinical characteristics, pathologic features, and prognostic factors were analyzed both at the initial diagnosis and at the diagnosis of brain metastases. Endocrine therapy for patients with luminal subtypes was further studied.
The median age of patients was 46 years (range 28-74 years). The median survival time was 8.0 months (range, 0-80 months), the 1-year survival rate was 32% and the 5-year survival rate was 4%. The time to brain metastasis differed according to clinical stage at the initial diagnosis, and the time for patients with the luminal A subtype was the longest (P < 0.001). Multivariate analysis demonstrated that performance status score > 1, multiple brain metastases and without whole brain radiotherapy (WBRT) in combination with chemotherapy were associated with poor prognosis. Compared with the luminal A subtype, features of the HER-2 and TN subtypes included early metastases, rapid progression after first-line treatment (8.0 months vs. 11.0 months), and poor overall survival (25.0 months vs. 63.0 months). The luminal A subtype showed a tendency for good prognosis and slow growth. Tamoxifen could improve the survival of luminal A/B subtypes (median survival 24.0 months vs. 7.0 months, respectively, P = 0.002).
The prognosis of brain metastases from breast cancer was poor, especially in patients with HER-2 and TN subtypes. Generally, WBRT in combination with chemotherapy was the standard treatment modality. Patients with the luminal subtypes could benefit from tamoxifen.
Chinese journal of cancer 04/2010; 29(4):413-9.
-
[show abstract]
[hide abstract]
ABSTRACT: Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors. The aim of our study was to determine the prevalence of abnormalities in the hematologic profile in patients with colorectal cancer before treatment and to evaluate if such a profile could be used for prognostic evaluations. We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as colorectal cancers between May 2005 and August 2009. All subjects were investigated regarding levels of white blood cells, platelets, and hemoglobin concentration. Survival was compared by using the log-rank test on the Kaplan-Meier life table. Multivariate Cox regression analysis was used to evaluate if the pretreatment hematologic profile was independent prognostic factor. We identified 363 patients with colorectal cancer and 315 patients with benign diseases for the final analysis. The percentages of leukocytosis, anemia, and thrombocytosis were significantly higher in colorectal cancer patients than in patients with benign diseases. Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival. The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival. The cumulative effect of anemia and thrombocytosis yielded shorter survival. Anemia and thrombocytosis can be considered as useful prognostic markers in patients with colorectal cancer.
Tumor Biology 03/2010; 31(4):255-60. · 1.94 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate the clinical characteristics and prognosis of patients with different subtypes of breast cancer: basaloid, HER-2 and luminal types, and try to find the evidence of individualized treatment for the patients.
1280 histologically and immunohistochemically proven patients with resectable breast cancer were treated, and the clinical data including characteristics, relapse and survival of the patients with different subtypes of breast cancer were analyzed retrospectively.
Of the 1280 breast cancer patients, basaloid, HER-2 and luminal types accounted for 20.9%, 23.2% and 55.9%, respectively. Basaloid type was more likely to be found in younger patients frequently with a family history of breast cancer. HER-2 type usually had a tumor of larger size with more advanced stage disease and more metastatic lymph nodes. Luminal type was likely to occur in aged patients with an earlier stage disease. The recurrence rates in basaloid, HER-2 and luminal types were 25.0%, 27.9% and 11.7%, respectively. Patients with basaloid or HER-2 type were found to have a significantly higher recurrence rate than the patients with luminal type breast cancer (P < 0.001), but no significant difference was observed between the basaloid and HER-2 types. However, patients with basaloid type breast cancer were more likely to develop lung metastasis than HER-2 type (13.4% vs. 7.1%, P = 0.017). Up to December 2006, the 5-year disease-free survival (DFS) rates for patients with basaloid, HER-2 and luminal types were 72.2%, 68.2% and 86.2% (P < 0.001), respectively. The overall 5-yr survival (OS) rates of the three groups were 88.6%, 83.8% and 95.8% (P < 0.001) , respectively. Of the patients with luminal type breast cancer, HER2-negative patients had a higher DFS (86.2% vs 57.0%, P < 0.001) and OS (95.8% vs 87.7%, P = 0.0001) compared with those with HER2-positive. The results of Multivariate Cox Regression showed that tumor size and lymph node state were the most important factors influencing the prognosis.
Each subtype of breast cancer has somewhat its own specific clinical features in terms of recurrence pattern and prognosis, therefore, individualized treatment regimen may be required.
Zhonghua zhong liu za zhi [Chinese journal of oncology] 07/2008; 30(6):456-61.
-
[show abstract]
[hide abstract]
ABSTRACT: Triple-negative breast cancer is defined by a lack of expression of estrogen receptor, progesterone receptor, and HER2/neu, and considered to be a clinicopathologic entity with aggressive behaviors and poor prognosis. No satisfactory treatment is available. This study was to analyze the clinical characteristics and prognostic factors of the patients with triple-negative breast cancer.
Clinical data of 1,280 patients with histopathologically confirmed resectable breast cancer, treated at Cancer Center of Sun Yat-sen University from Jan. 2000 to Dec. 2004, were analyzed. Of the 1,280 patients, 305 (23.8%) were confirmed to be triple-negative breast cancer. The clinical characteristics, recurrence and survival of the patients were summarized.
Triple-negative breast cancer was commonly seen in young patients, with large masses, a high proportion of lymph node metastasis and familial history of breast cancer at diagnosis. By Jun. 2007, the median time of follow-up was 52 months (range, 28-89 months). Of the 1,280 patients, 234 had local recurrence and metastasis, and 94 died. There was no significant difference in local recurrence between triple-negative and non-triple-negative breast cancer patients. However, the occurrence rates of lung metastasis (HR= 4.41, P<0.001) and liver metastasis (HR=2.13, P=0.006) were significantly higher in triple-negative breast cancer patients than in non-triple-negative breast cancer patients. The 5-year disease-free and overall survival rates were significantly lower in triple-negative breast cancer patients than in non-triple-negative breast cancer patients (73.7% vs. 80.8%, P=0.025; 88.5% vs. 92.8%,P=0.010). Multivariate Cox regression analysis showed that tumor size and lymph node state were prognostic factors of triple-negative breast cancer patients.
Nearly one fourth of breast cancer patients in China are triple-negative breast cancer patients. These patients are usually young, with large masses, lymph node metastasis, and family history of breast cancer. Lung metastasis and liver metastasis may be the main reason of poor prognosis of triple-negative breast cancer.
Ai zheng = Aizheng = Chinese journal of cancer 07/2008; 27(6):561-5.
-
[show abstract]
[hide abstract]
ABSTRACT: Few treatment options are available for metastatic breast cancer with resistance to both anthracycline-and taxane-based chemotherapy regimens. Docetaxel combined capecitabine (DC regimen) is approved as a new active regimen for metastatic breast cancer. This study was to explore the efficacy of DC regimen on metastatic breast cancer, and evaluate its safety.
A total of 31 metastatic breast cancer patients received DC regimen during each 3-week chemotherapy cycle. All patients received oral administration of capecitabine (1250 mg/m(2)) twice daily, within 30 min after meal on day 1 to Day 14, and infusion of docetaxel (75 mg/m(2)) on the first day of each 3-week cycle. All patients received prophylactic therapy with oral dexamethasone (8 mg) twice daily on 3 successive days.
A total of 116 cycles of DC regimen were administered, with a median of 3.7 cycles. The objective response rate was 41.9%, with a complete remission (CR) rate of 9.6%. The most frequent treatment-related adverse events were fatigue, leukopenia, nausea, vomiting, hand-foot syndrome, and stomatitis. The median follow-up was 10.8 months (range 2-23 months). Two patients were died of tumor progression.
The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer.
Ai zheng = Aizheng = Chinese journal of cancer 04/2007; 26(4):407-10.
-
[show abstract]
[hide abstract]
ABSTRACT: The majority of small cell carcinoma occurs in the lung. Extrapulmonary small cell carcinoma (ESCC) has been recognized as a clinicopathologic entity distinct from small cell carcinoma of the lung. The study was to investigate the clinical characteristics, therapy, and prognosis of ESCC.
The medical records, from Jan. 1985 to Dec. 2005, of 53 patients with pathologically proved ESCC were analyzed retrospectively.
Of the 53 patients, 39 were men and 14 were women, with the median age of 53 years (range, 27-76 years). Of the 53 cases of ESCC, 33 (62.3%) were detected in the esophagus, 5 in the cervix, 4 in the larynx, 3 in the pharynx, 2 in the upper sinus, 2 in the rectum and sublingual gland, 1 in the thyroid gland, 1 in the pleura, and 1 in the liver. Forty patients (75.5%) had limited disease (LD) and 13 (24.5%) had extensive disease (ED). Patients with ED mostly received platinum-based chemotherapy, for which the response rate was 69.2%. Patients with LD were treated with a variety of therapeutic modalities: 7 were treated with surgery plus radiochemotherapy, 3 with surgery plus radiotherapy, 18 with surgery plus chemotherapy, 6 with radiotherapy plus chemotherapy, 4 with radiotherapy alone, and 2 with chemotherapy alone. The median survival time (MST) was 20 months for all patients, and the 1-and 3-year survival rates were 41.3% and 31.4%. MST for patients with ED and LD were 15 months and 26 months, respectively, and 1-and 3-year survival rates were 51.1% vs. 14.4%, and 42.5% vs. 0% (P=0.017 ).
ESCC is identified in various sites, with the most common primary site being the esophagus. Multimodality therapy has become increasingly used for the majority of patients with LD-ESCC. Combination chemotherapy has been a major treatment for patients with ED-ESCC. Generally, the prognosis of LD-ESCC is significantly superior to ED-ESCC.
Ai zheng = Aizheng = Chinese journal of cancer 09/2006; 25(9):1131-3.
-
[show abstract]
[hide abstract]
ABSTRACT: Toxicities and their severities vary among advanced gastric cancer patients when they receive the same regimen containing continuous infusion of 5-fluorouracil (5-FU). Dihydropyrimidine dehydrogenase (DPD) is the key rate-limiting enzymes which is closely related to toxicities of 5-FU in chemotherapy. This study was to explore the relationship between activity of DPD and concentration of 5-FU, and their correlation to adverse events among advanced gastric cancer patients treated with the same regimen containing 5-FU continuous infusion.
Patients received the same regimen (intravenous injection of paclitaxel 75 mg/m(2), leucovorin 200 mg/m(2) and 5-FU 375 mg/m(2), continuous infusion of 5-FU 2.5 g/m2 for 46 hours every two weeks). The peripheral blood was collected from 36 patients with advanced gastric cancer before and after chemotherapy to detect the activity of DPD and concentration of 5-FU by high-performance liquid chromatography (HPLC). Adverse events were assessed every cycle.
Serum activity of DPD revealed a unimodel distribution, which globally fits to a guassian distribution (range 1.56-6.01). Mean and median DPD activity values were 2.38 and 2.13, respectively. No total DPD deficiency was found in the patients. The concentration of 5-FU varied from 179.2 microg/L to 1 589.2 microg/L, which demonstrated normality distribution after a logarithmic transformation was applied. The DPD activity was inversely correlated with 5-FU concentration (r=-0.376, P=0.024). The patients with low activity of DPD were more frequently suffering from severe diarrhea, mucositis, and myelosuppression. And high level of 5-FU concentration led to the increase of adverse events.
Pre-chemotherapy DPD activity and 5-FU concentration during chemotherapy vary among gastric cancer patients, which may help to prevent severe toxicities during the treatment.
Ai zheng = Aizheng = Chinese journal of cancer 08/2006; 25(8):1039-43.
-
[show abstract]
[hide abstract]
ABSTRACT: Multidrug resistance is one of the main causes of treatment failure of chemotherapy. Reversal agents may be used to reverse drug-resistance. To date, no appropriate reversal agent is used clinically. This study was to evaluate reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin (DDP), and to explore its mechanisms.
Lung adenocarcinoma cell line A549 and its DDP-resistant cell line A549/DDP were treated with DDP and H101. Reverse effect of H101 on drug-resistance of A549/DDP to DDP was tested by MTT assay. The levels of cellular multidrug resistant protein 1 (MRP1), glutathione-S-transferase (GST), and topoisomerase-II (TOPO-II) were detected by flow cytometry (FCM). The level of intracellular glutathione (GSH) was measured by fluorescence-Coomassie light blue method. The intracellular concentration of platinum was measured by atomic absorption spectrometry.
The resistance index of A549/DDP cells to DDP was 14.3. After infection of H101, the 50% inhibitory concentration (IC(50)) of DDP to A549/DDP cells reduced from 352.4 micromol/L to 61.6 micromol/L by 5.7 folds. Protein levels of GST and TOPO-II were higher in A549/DDP cells than in A549 cells, which were markedly decreased in A549/DDP cells after infection of H101. No MRP1 protein was detected in both A549 cells and A549/DDP cells. Intracellular amount of GSH in A549/DDP cells was 2 times higher than that in A549 cells, which was significantly decreased after infection of H101. The concentration of platinum in A549 cells was 3 times higher than that in A549/DDP cells. After infection of H101, the concentration of platinum in A549 cells had no significant change, but that in A549/DDP cells was significantly increased.
H101 may reverse drug-resistance of A549/DDP cells to DDP through down-regulating GST and TOPO-IIand increasing intracellular cumulation of platinum.
Ai zheng = Aizheng = Chinese journal of cancer 08/2005; 24(8):975-9.
-
[show abstract]
[hide abstract]
ABSTRACT: The effect of adenovirus, a kind of oncolytic virus and a kind of carrier in gene therapy, depends on the expression of Coxsackie and adenovirus receptor (CAR) on cell surface to a large degree. This study was to evaluate relationship of CAR expression to infectivity and efficacy of adenovirus.
Pathologic specimens from 29 patients in a clinical trial of genetically modified adenovirus (H101) were collected. Expression of CAR in cancer tissues was detected by immuohistochemistry. Expression of CAR on cancer cell membrane was detected by flow cytometry (FCM). Inhibitory effect of H101 on cells was assessed by MTT assay.
Positive rate of CAR was significantly higher in patients achieved complete remission (CR) or partial remission (PR) than in patients had stable disease (SD) or progressive disease (PD) [70.0% (7/10) vs. 31.6% (6/19), P=0.048]. CAR expression on different cells was different, and the amount of CAR was positively related to virus infectivity, presented as the inhibitory rate of H101-infected cells (r=0.986).
The expression of CAR closely relates to antitumor activity and efficacy of adenovirus. Also, the efficacy of adenovirus is higher on cancers with increased CAR expression than on those with decreased CAR expression.
Ai zheng = Aizheng = Chinese journal of cancer 04/2005; 24(4):502-5.
-
Yi-Fu He,
Yu-Hong Li,
Hui-Qiang Huang,
Zhong-Jun Xia,
Xiao-Fei Sun,
Tong-Yu Lin,
Xu-Bin Lin, Zhong-Yu Yuan,
Zhi-Ming Li,
Feng-Hua Wang,
Shu-Sen Wang,
Wen-Qi Jiang
[show abstract]
[hide abstract]
ABSTRACT: Gastrointestinal tract is the most common extranodal involvement site of non-Hodgkin's lymphoma (NHL). However, no standard treatment regimen has ever been established for primary gastric NHL (PGNHL). This paper was to summarize the clinical characteristics and treatment results of PGNHL patients.
Records of 59 PGNHL patients, treated from Jan. 1980 to Jan. 2002 in Cancer Center of Sun Yat-sen University, were reviewed to summarize their clinical characteristics, and influence of treatment modality on their survival.
Of the 59 PGNHL patients, 46 (78.0%) were in stage I/II. According to Working Formulation, most of them were in intermediate grade (46, 78.0%). The most common immune phenotype was B-cell lineage (46/49, 93.9%). These patients were treated with chemotherapy plus surgery (37,62.7%), chemotherapy alone (17,28.8%), and surgery alone (5,8.5%), respectively. The 2-, 5-, and 10-year survival rates of the 59 patients were 76.4%,63.7%, and 42.5%, respectively. For those patients in intermediate grade (including immunoblastic cell lymphoma), there was no significant difference in the 5-year survival rate between the patients received chemotherapy plus surgery and the patients received chemotherapy alone (52.5% vs. 57.1%).
Chemotherapy-dominated modality is recommended for patients with PGNHL of intermediate or high grade. The effect of surgery on PGNHL needs to be confirmed by prospective randomized trial.
Ai zheng = Aizheng = Chinese journal of cancer 04/2005; 24(4):475-7.
-
Rui-Hua Xu, Zhong-Yu Yuan,
Zhong-Zhen Guan,
Ye Cao,
Hua-Qing Wang,
Xiao-Hua Hu,
Ji-Feng Feng,
Yang Zhang,
Fang Li,
Zheng-Tang Chen,
Jie-Jun Wang,
Jian-Jin Huang,
Qing-Hua Zhou,
San-Tai Song
[show abstract]
[hide abstract]
ABSTRACT: In recent years,great development have been made in cancer therapeutics with replication-competent viruses (oncolytic viruses), E1B deleted adenovirus is one of promising viruses. The current study was designed to evaluate the efficacy and toxicity of intratumoral H101, a E1B-deleted adenovirus, in combination with chemotherapy on patients with cancer.
A total of 50 patients with malignant tumors in multiple centers clinical trial were treated with H101, 0.5ml 5x10(11) viral particle per day for 5 consecutive days every three weeks. Routine chemotherapy was performed at the same time. And the efficacy and toxicity were recorded.
Among 46 valuable cases, the overall response rate was 30.4%. The response rate was 28.0% (14/50) among ITT population, including 3 complete response (CR) and 11 partial response (PR). The overall response rate of control lesion was 13.0%, including 1 case of CR and 5 cases of PR. Thus, the response rate in injected lesion is clearly higher than that in control lesion (P< 0.001). Main side effects were injection site pain (26.9%) and fever (30.2%). Grade 1 hepatic dysfunction was found in 4 patients, grade 2 in 1 patients, grade 4 in 1 patients. Grade 4 hematological toxicities were found in 4 patients.
The study showed that the combination of genetically modified adenovirus (H101) and chemotherapy possessed some effect for treating the patients with refractory malignant tumors, and the toxicities were lower, well tolerated.
Ai zheng = Aizheng = Chinese journal of cancer 01/2004; 22(12):1307-10.
-
[show abstract]
[hide abstract]
ABSTRACT: The side effects of glucocorticoid, for example inducing or sharpening diabetes, should be considered in treatment of non-Hodgkin's lymphoma (NHL) accompanied by diabetes mellitus with CHOP regimen[Adriamycin(doxorubicin)+cyclophosphamide+Oncovin(Vincristine)+prednisone]. The study was performed to compare the efficacy and toxicity of CHO (without prednisone) and standard CHOP regimen.
From June 1991 to May 1999, 53 patients with histologically and immunohistochemically proven of intermediate-grade NHL accompanied by diabetes mellitus were analyzed retrospectively.
Twenty-two patients received CHO regimen and thirty-one received CHOP regimen. Patients in both groups were well- matched with baseline disease characteristics (P >0.05). In CHO group,the response rate was 81.8%;whereas in CHOP group,the response rate was 90.4%. The median survival of CHO group and CHOP group were 31 months and 33 months,respectively. The three-year survival rate and three-year disease- free survival rate in CHO group were 44.1% and 31.2% respectively versus 47.3% and 33.8% in CHOP group. For the side effects, there were differences between two groups except nausea and vomiting which were obvious in CHO group (P=0.015).
CHO regimen may be selected in treatment of intermediate-grade NHL accompanied by diabetes mellitus. The efficacy and the toxicity of CHO regimen is similar to standard CHOP regimen. Whether it is true should be confirmed by well-controlled randomized clinical trials with more patients.
Ai zheng = Aizheng = Chinese journal of cancer 04/2003; 22(4):393-6.
